|Bid||48.67 x 1000|
|Ask||49.88 x 800|
|Day's Range||48.94 - 49.52|
|52 Week Range||44.76 - 54.26|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||8.49|
|Forward Dividend & Yield||1.93 (3.70%)|
|Ex-Dividend Date||May 03, 2021|
|1y Target Est||63.40|
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent asthmaData reinforce well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. – October 20, 2021 - The U.S. Food and D
The unit, Express Scripts, said it expects cost savings of $20 million in 2022 by preferring the Semglee injection. Drugmakers such as Eli Lilly, Sanofi and Novo Nordisk have been under pressure to make their insulin products more affordable amid heavy criticism from lawmakers and patients in a country with a diabetes problem.